Jackie Kleynhans
Overview
Explore the profile of Jackie Kleynhans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
449
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Y, Knoll M, Herbert C, Bennett J, Feikin D, Garcia Quesada M, et al.
J Infect
. 2025 Jan;
90(3):106426.
PMID: 39864526
Background: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13...
2.
Garcia Quesada M, Peterson M, Bennett J, Hayford K, Zeger S, Yang Y, et al.
Lancet Infect Dis
. 2024 Dec;
PMID: 39706205
Background: Widespread use of pneumococcal conjugate vaccines (PCVs) has reduced vaccine-type invasive pneumococcal disease (IPD). We describe the serotype distribution of IPD after extensive use of ten-valent PCV (PCV10; Synflorix,...
3.
Cohen C, du Plessis M, Martinson N, Moyes J, Walaza S, Wolter N, et al.
J Infect Dis
. 2024 Nov;
231(2):e328-e336.
PMID: 39542652
Background: Approaches for determining whether influenza vaccination prevents infection, attenuates illness, or both are important for developing improved vaccines. We estimated influenza infection incidence and evaluated symptom ascertainment methodologies in...
4.
Lekhuleni C, Ndlangisa K, Gladstone R, Chochua S, Metcalf B, Li Y, et al.
Nat Commun
. 2024 Sep;
15(1):8401.
PMID: 39333488
Invasive pneumococcal disease (IPD) due to non-vaccine serotypes after the introduction of pneumococcal conjugate vaccines (PCV) remains a global concern. This study used pathogen genomics to evaluate changes in invasive...
5.
Ko S, Radecki P, Belinky F, Bhiman J, Meiring S, Kleynhans J, et al.
Nat Commun
. 2024 Aug;
15(1):7240.
PMID: 39174553
Previous studies have linked the evolution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic variants to persistent infections in people with immunocompromising conditions, but the processes responsible for these observations...
6.
von Gottberg A, Kleynhans J, de Gouveia L, Tempia S, Meiring S, Quan V, et al.
Lancet Glob Health
. 2024 Aug;
12(9):e1470-e1484.
PMID: 39151982
Background: In South Africa, 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2009 and 13-valent PCV (PCV13) was introduced in 2011, both in a two plus one schedule. We evaluated...
7.
Els F, Kleynhans J, Wolter N, du Plessis M, Moosa F, Tempia S, et al.
S Afr J Infect Dis
. 2024 Aug;
39(1):574.
PMID: 39114258
Background: Comparisons of the characteristics of individuals hospitalised with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or seasonal influenza in low-to middle-income countries with high human immunodeficiency virus (HIV) prevalence...
8.
Sun K, Bhiman J, Tempia S, Kleynhans J, Madzorera V, Mkhize Q, et al.
Nat Med
. 2024 Jul;
30(10):2805-2812.
PMID: 39060660
Serum neutralizing antibodies (nAbs) induced by vaccination have been linked to protection against symptomatic and severe coronavirus disease 2019. However, much less is known about the efficacy of nAbs in...
9.
Bishop K, Meiring S, Tempia S, von Gottberg A, Wolter N, Kleynhans J, et al.
Influenza Other Respir Viruses
. 2024 Apr;
18(5):e13300.
PMID: 38666359
Background: Identifying children at risk for severe COVID-19 disease from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may guide future mitigation interventions. Using sentinel surveillance data, we aimed to identify...
10.
Waterlow N, Kleynhans J, Wolter N, Tempia S, Eggo R, Hellferscee O, et al.
BMC Med
. 2024 Mar;
22(1):128.
PMID: 38515097
No abstract available.